IE75203B1 - 5-HT1-like receptor agonist for rectal administration - Google Patents
5-HT1-like receptor agonist for rectal administrationInfo
- Publication number
- IE75203B1 IE75203B1 IE930339A IE930339A IE75203B1 IE 75203 B1 IE75203 B1 IE 75203B1 IE 930339 A IE930339 A IE 930339A IE 930339 A IE930339 A IE 930339A IE 75203 B1 IE75203 B1 IE 75203B1
- Authority
- IE
- Ireland
- Prior art keywords
- pharmaceutical composition
- active ingredient
- pct
- rectal administration
- hard fat
- Prior art date
Links
- 239000000018 receptor agonist Substances 0.000 title abstract description 4
- 229940044601 receptor agonist Drugs 0.000 title abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 239000002585 base Substances 0.000 claims abstract description 11
- 239000012458 free base Substances 0.000 claims abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 7
- 229940116364 hard fat Drugs 0.000 claims abstract description 6
- 239000007909 solid dosage form Substances 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 18
- 239000000829 suppository Substances 0.000 claims description 12
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 20
- 208000019695 Migraine disease Diseases 0.000 description 7
- 206010027599 migraine Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000003752 saphenous vein Anatomy 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- PORMUFZNYQJOEI-UHFFFAOYSA-N sumatriptan succinate Chemical compound OC(=O)CCC(O)=O.CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 PORMUFZNYQJOEI-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929209882A GB9209882D0 (en) | 1992-05-07 | 1992-05-07 | Compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE930339A1 IE930339A1 (en) | 1993-11-17 |
| IE75203B1 true IE75203B1 (en) | 1997-08-27 |
Family
ID=10715158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE930339A IE75203B1 (en) | 1992-05-07 | 1993-05-06 | 5-HT1-like receptor agonist for rectal administration |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US5705506A (OSRAM) |
| EP (1) | EP0639072B1 (OSRAM) |
| JP (1) | JPH07506570A (OSRAM) |
| KR (1) | KR100253111B1 (OSRAM) |
| AT (1) | ATE163850T1 (OSRAM) |
| AU (1) | AU670083B2 (OSRAM) |
| BE (1) | BE1007024A5 (OSRAM) |
| BG (1) | BG62120B1 (OSRAM) |
| BR (1) | BR1100108A (OSRAM) |
| CA (1) | CA2135179C (OSRAM) |
| CH (1) | CH685920A5 (OSRAM) |
| CY (1) | CY2039B1 (OSRAM) |
| CZ (1) | CZ283512B6 (OSRAM) |
| DE (1) | DE69317418T2 (OSRAM) |
| ES (1) | ES2113533T3 (OSRAM) |
| FR (1) | FR2690847B1 (OSRAM) |
| GB (2) | GB9209882D0 (OSRAM) |
| GR (1) | GR3026584T3 (OSRAM) |
| HK (1) | HK95697A (OSRAM) |
| HU (2) | HU227338B1 (OSRAM) |
| IE (1) | IE75203B1 (OSRAM) |
| IL (1) | IL105468A (OSRAM) |
| IT (1) | IT1261471B (OSRAM) |
| NO (1) | NO306700B1 (OSRAM) |
| NZ (1) | NZ252132A (OSRAM) |
| OA (1) | OA10109A (OSRAM) |
| RO (1) | RO112993B1 (OSRAM) |
| RU (1) | RU2118527C1 (OSRAM) |
| SG (1) | SG46649A1 (OSRAM) |
| TW (1) | TW231970B (OSRAM) |
| UA (1) | UA37206C2 (OSRAM) |
| WO (1) | WO1993021916A1 (OSRAM) |
| ZA (1) | ZA933178B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997044062A1 (en) * | 1996-05-23 | 1997-11-27 | Alcon Laboratories, Inc. | The use of 5-ht1b/1d agonists to treat ocular pain |
| US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
| HRP20000707B1 (en) * | 1998-03-26 | 2005-06-30 | Fujisawa Pharmaceutical Co. | Sustained release preparations |
| US7704958B1 (en) * | 1999-03-05 | 2010-04-27 | Bio Holding, Inc. | Methods and compositions for inhibiting apoptosis using serine protease inhibitors |
| AR056690A1 (es) * | 2005-10-14 | 2007-10-17 | Athersys Inc | Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc |
| EP2124556B1 (en) | 2006-10-09 | 2014-09-03 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| CA2749273C (en) | 2008-01-09 | 2018-09-04 | Charleston Laboratories, Inc. | Pharmaceutical oral dosage form comprising a triptan and an antiemetic |
| EP2451274B1 (en) | 2009-07-08 | 2017-10-04 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| CN103402514B (zh) | 2010-10-15 | 2016-01-13 | 康特拉医药公司 | 用于治疗运动障碍的血清素受体激动剂组合物 |
| KR102104635B1 (ko) | 2012-04-18 | 2020-04-27 | 콘테라 파르마 에이피에스 | 운동 장애의 개선된 관리에 적합한 경구로 이용 가능한 약학적 제형 |
| US10179109B2 (en) | 2016-03-04 | 2019-01-15 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates |
| CN109689036A (zh) | 2016-07-11 | 2019-04-26 | 康特拉医药公司 | 用于治疗早晨运动不能的脉冲药物输送系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2082175B (en) * | 1980-08-12 | 1984-05-02 | Glaxo Group Ltd | Heterocyclic compounds |
| CH652394A5 (fr) * | 1980-08-12 | 1985-11-15 | Glaxo Group Ltd | Derives indoliques, leur preparation et medicaments les renfermant. |
| ZW19381A1 (en) * | 1980-08-12 | 1983-03-09 | Glaxo Group Ltd | Heterocyclic compounds |
| GR79215B (OSRAM) * | 1982-06-07 | 1984-10-22 | Glaxo Group Ltd | |
| HU196752B (en) * | 1983-12-06 | 1989-01-30 | Glaxo Group Ltd | Process for production of medical compositions containing indole-derivatives and these compounds |
| GB2162522B (en) * | 1984-08-01 | 1988-02-24 | Glaxo Group Ltd | An indole derivative |
| GB8419575D0 (en) * | 1984-08-01 | 1984-09-05 | Glaxo Group Ltd | Chemical compounds |
| NL8503337A (nl) * | 1984-12-04 | 1986-07-01 | Glaxo Group Ltd | Indoolderivaten. |
| GB8431426D0 (en) * | 1984-12-13 | 1985-01-23 | Glaxo Group Ltd | Chemical compounds |
| DE3678805D1 (de) * | 1985-11-08 | 1991-05-23 | Glaxo Group Ltd | Indolderivate. |
| ATE92057T1 (de) * | 1987-08-13 | 1993-08-15 | Glaxo Group Ltd | Indol-derivate. |
| DK0486666T3 (da) * | 1990-06-07 | 1998-03-30 | Zeneca Ltd | Terapeutisk heterocykliske forbindelser |
-
1992
- 1992-05-07 GB GB929209882A patent/GB9209882D0/en active Pending
-
1993
- 1993-04-20 IL IL10546893A patent/IL105468A/en not_active IP Right Cessation
- 1993-05-03 JP JP5518928A patent/JPH07506570A/ja active Pending
- 1993-05-03 AU AU40640/93A patent/AU670083B2/en not_active Ceased
- 1993-05-03 CZ CZ942723A patent/CZ283512B6/cs not_active IP Right Cessation
- 1993-05-03 DE DE69317418T patent/DE69317418T2/de not_active Expired - Lifetime
- 1993-05-03 NZ NZ252132A patent/NZ252132A/en not_active IP Right Cessation
- 1993-05-03 HU HU9403188A patent/HU227338B1/hu unknown
- 1993-05-03 WO PCT/EP1993/001077 patent/WO1993021916A1/en not_active Ceased
- 1993-05-03 US US08/331,485 patent/US5705506A/en not_active Expired - Fee Related
- 1993-05-03 RU RU94046069/14A patent/RU2118527C1/ru not_active IP Right Cessation
- 1993-05-03 CA CA002135179A patent/CA2135179C/en not_active Expired - Fee Related
- 1993-05-03 UA UA94115989A patent/UA37206C2/uk unknown
- 1993-05-03 EP EP93909884A patent/EP0639072B1/en not_active Expired - Lifetime
- 1993-05-03 RO RO94-01790A patent/RO112993B1/ro unknown
- 1993-05-03 ES ES93909884T patent/ES2113533T3/es not_active Expired - Lifetime
- 1993-05-03 AT AT93909884T patent/ATE163850T1/de active
- 1993-05-05 SG SG1996007136A patent/SG46649A1/en unknown
- 1993-05-05 GB GB9309209A patent/GB2266665B/en not_active Expired - Lifetime
- 1993-05-06 CH CH139793A patent/CH685920A5/fr not_active IP Right Cessation
- 1993-05-06 IE IE930339A patent/IE75203B1/en not_active IP Right Cessation
- 1993-05-06 FR FR9305432A patent/FR2690847B1/fr not_active Expired - Lifetime
- 1993-05-06 IT ITRM930286A patent/IT1261471B/it active IP Right Grant
- 1993-05-06 BE BE9300467A patent/BE1007024A5/fr not_active IP Right Cessation
- 1993-05-06 ZA ZA933178A patent/ZA933178B/xx unknown
- 1993-05-12 TW TW082103742A patent/TW231970B/zh active
-
1994
- 1994-11-04 NO NO944214A patent/NO306700B1/no not_active IP Right Cessation
- 1994-11-04 OA OA60578A patent/OA10109A/en unknown
- 1994-11-05 KR KR1019940703950A patent/KR100253111B1/ko not_active Expired - Fee Related
- 1994-11-07 BG BG99167A patent/BG62120B1/bg unknown
-
1995
- 1995-06-29 HU HU95P/P00531P patent/HU211638A9/hu unknown
-
1996
- 1996-12-24 BR BR1100108-9A patent/BR1100108A/pt active IP Right Grant
-
1997
- 1997-06-26 HK HK95697A patent/HK95697A/xx not_active IP Right Cessation
-
1998
- 1998-04-10 GR GR980400773T patent/GR3026584T3/el unknown
- 1998-04-30 CY CY9802039A patent/CY2039B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5705506A (en) | Pharmaceutical compositions of alkylsulphonamides 5HT1 agonists for rectal administration | |
| RU2146140C1 (ru) | Средство для лечения нарушений сна и фармацевтическая композиция на его основе | |
| CZ288834B6 (cs) | Farmaceutický prostředek k ošetřování desynchronizačních poruch | |
| AP544A (en) | Compositions for rectal administration | |
| EP0671908B1 (en) | Pharmaceutical compositions comprising 5-ht 1? receptor agonists and absorption enhancers | |
| JPH11507671A (ja) | 良性前立腺過形成を処置するためのメラトニンアゴニスト | |
| AU3810100A (en) | Stable pharmaceutical application form for paroxetin anhydrate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK9A | Patent expired |